Clinical aspects of influenza A (H1N1) in HIV-infected individuals in São Paulo during the pandemic of 2009

OBJECTIVE: To describe the clinical aspects of H1N1 among HIV coinfected patients seen at a reference center for AIDS treatment in São Paulo, Brazil. Design: Observational and prospective cohort study. METHODS: Descriptive study of clinical and laboratory investigation of HIV-infected patients with confirmed diagnosis of influenza A (H1N1) in 2009. We analyzed patients monitored in CRT/DST/AIDS, a specialized service for people living with HIV, located in São Paulo, Brazil. RESULTS: 108 individuals presented with symptoms of H1N1 infection at the CRT DST/AIDS in 2009. Eighteen patients (16.7%) had confirmation of the diagnosis of influenza A. Among the confirmed cases, ten (55.6%) were hospitalized and eight (44.4%) were outpatients. Dyspnea was present in nine patients (50%), hemoptysis in three (16%). Six patients (60%) required therapy with supplemental oxygen. All patients had good clinical outcomes and none died. CONCLUSIONS: In our hospital, the symptoms that led patients to seek medical care were similar to the common flu. Hospital admission and the early introduction of antibiotics associated with oseltamivir may have been the cause of the favorable outcome of our cases

Neotropical freshwater fisheries : A dataset of occurrence and abundance of freshwater fishes in the Neotropics

The Neotropical region hosts 4225 freshwater fish species, ranking first among the world's most diverse regions for freshwater fishes. Our NEOTROPICAL FRESHWATER FISHES data set is the first to produce a large-scale Neotropical freshwater fish inventory, covering the entire Neotropical region from Mexico and the Caribbean in the north to the southern limits in Argentina, Paraguay, Chile, and Uruguay. We compiled 185,787 distribution records, with unique georeferenced coordinates, for the 4225 species, represented by occurrence and abundance data. The number of species for the most numerous orders are as follows: Characiformes (1289), Siluriformes (1384), Cichliformes (354), Cyprinodontiformes (245), and Gymnotiformes (135). The most recorded species was the characid Astyanax fasciatus (4696 records). We registered 116,802 distribution records for native species, compared to 1802 distribution records for nonnative species. The main aim of the NEOTROPICAL FRESHWATER FISHES data set was to make these occurrence and abundance data accessible for international researchers to develop ecological and macroecological studies, from local to regional scales, with focal fish species, families, or orders. We anticipate that the NEOTROPICAL FRESHWATER FISHES data set will be valuable for studies on a wide range of ecological processes, such as trophic cascades, fishery pressure, the effects of habitat loss and fragmentation, and the impacts of species invasion and climate change. There are no copyright restrictions on the data, and please cite this data paper when using the data in publications

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2) : results of a randomised, double-blind, placebo-controlled, phase 3 trial

Background Despite the availability of effective vaccines against COVID-19, booster vaccinations are needed to maintain vaccine-induced protection against variant strains and breakthrough infections. This study aimed to investigate the efficacy, safety, and immunogenicity of the Ad26.COV2.S vaccine (Janssen) as primary vaccination plus a booster dose. Methods ENSEMBLE2 is a randomised, double-blind, placebo-controlled, phase 3 trial including crossover vaccination after emergency authorisation of COVID-19 vaccines. Adults aged at least 18 years without previous COVID-19 vaccination at public and private medical practices and hospitals in Belgium, Brazil, Colombia, France, Germany, the Philippines, South Africa, Spain, the UK, and the USA were randomly assigned 1:1 via a computer algorithm to receive intramuscularly administered Ad26.COV2.S as a primary dose plus a booster dose at 2 months or two placebo injections 2 months apart. The primary endpoint was vaccine efficacy against the first occurrence of molecularly confirmed moderate to severe-critical COVID-19 with onset at least 14 days after booster vaccination, which was assessed in participants who received two doses of vaccine or placebo, were negative for SARS-CoV-2 by PCR at baseline and on serology at baseline and day 71, had no major protocol deviations, and were at risk of COVID-19 (ie, had no PCR-positive result or discontinued the study before day 71). Safety was assessed in all participants; reactogenicity, in terms of solicited local and systemic adverse events, was assessed as a secondary endpoint in a safety subset (approximately 6000 randomly selected participants). The trial is registered with ClinicalTrials.gov, NCT04614948, and is ongoing. Findings Enrolment began on Nov 16, 2020, and the primary analysis data cutoff was June 25, 2021. From 34 571 participants screened, the double-blind phase enrolled 31 300 participants, 14 492 of whom received two doses (7484 in the Ad26.COV2.S group and 7008 in the placebo group) and 11 639 of whom were eligible for inclusion in the assessment of the primary endpoint (6024 in the Ad26.COV2.S group and 5615 in the placebo group). The median (IQR) follow-up post-booster vaccination was 36 center dot 0 (15 center dot 0-62 center dot 0) days. Vaccine efficacy was 75 center dot 2% (adjusted 95% CI 54 center dot 6-87 center dot 3) against moderate to severe-critical COVID-19 (14 cases in the Ad26.COV2.S group and 52 cases in the placebo group). Most cases were due to the variants alpha (B.1.1.7) and mu (B.1.621); endpoints for the primary analysis accrued from Nov 16, 2020, to June 25, 2021, before the global dominance of delta (B.1.617.2) or omicron (B.1.1.529). The booster vaccine exhibited an acceptable safety profile. The overall frequencies of solicited local and systemic adverse events (evaluated in the safety subset, n=6067) were higher among vaccine recipients than placebo recipients after the primary and booster doses. The frequency of solicited adverse events in the Ad26.COV2.S group were similar following the primary and booster vaccinations (local adverse events, 1676 [55 center dot 6%] of 3015 vs 896 [57 center dot 5%] of 1559, respectively; systemic adverse events, 1764 [58 center dot 5%] of 3015 vs 821 [52 center dot 7%] of 1559, respectively). Solicited adverse events were transient and mostly grade 1-2 in severity. Interpretation A homologous Ad26.COV2.S booster administered 2 months after primary single-dose vaccination in adults had an acceptable safety profile and was efficacious against moderate to severe-critical COVID-19. Studies assessing efficacy against newer variants and with longer follow-up are needed. Funding Janssen Research & Development. Copyright (c) 2022 The Author(s). Published by Elsevier Ltd

Measurement of the K+→π+γγK^+\to\pi^+\gamma\gamma decay

International audienceA sample of 3984 candidates of the $K^+\to\pi^+\gamma\gamma$ decay, with an estimated background of $291\pm14$ events, was collected by the NA62 experiment at CERN during 2017-2018. In order to describe the observed di-photon mass spectrum, the next-to-leading order contribution in chiral perturbation theory was found to be necessary. The decay branching ratio in the full kinematic range is measured to be $(9.61\pm0.17)\times10^{-7}$. The first search for production and prompt decay of an axion-like particle with gluon coupling in the process $K^+\to\pi^+a$, $a\to\gamma\gamma$ is also reported

Search for K+K^+ decays into the π+e+e−e+e−\pi^+e^+e^-e^+e^- final state

International audienceThe first search for ultra-rare $K^+$ decays into the $\pi^+e^+e^-e^+e^-$ final state is reported, using a dataset collected by the NA62 experiment at CERN in 2017-2018. An upper limit of $1.4\times 10^{-8}$ at 90% CL is obtained for the branching ratio of the $K^+\to\pi^+e^+e^-e^+e^-$ decay, predicted in the Standard Model to be $(7.2\pm0.7)\times 10^{-11}$. Upper limits at 90% CL are obtained at the level of $10^{-9}$ for the branching ratios of two prompt decay chains involving pair-production of hidden-sector mediators: $K^+\to\pi^+aa$, $a\to e^+e^-$ and $K^+\to\pi^+S$, $S\to A^\prime A^\prime$, $A^\prime\to e^+e^-$. The QCD axion is excluded as a possible explanation of the "17 MeV anomaly"

Measurement of the K+→π+γγK^+\to\pi^+\gamma\gamma decay

International audienceA sample of 3984 candidates of the $K^+\to\pi^+\gamma\gamma$ decay, with an estimated background of $291\pm14$ events, was collected by the NA62 experiment at CERN during 2017-2018. In order to describe the observed di-photon mass spectrum, the next-to-leading order contribution in chiral perturbation theory was found to be necessary. The decay branching ratio in the full kinematic range is measured to be $(9.61\pm0.17)\times10^{-7}$. The first search for production and prompt decay of an axion-like particle with gluon coupling in the process $K^+\to\pi^+a$, $a\to\gamma\gamma$ is also reported

Search for K+K^+ decays into the π+e+e−e+e−\pi^+e^+e^-e^+e^- final state

International audienceThe first search for ultra-rare $K^+$ decays into the $\pi^+e^+e^-e^+e^-$ final state is reported, using a dataset collected by the NA62 experiment at CERN in 2017-2018. An upper limit of $1.4\times 10^{-8}$ at 90% CL is obtained for the branching ratio of the $K^+\to\pi^+e^+e^-e^+e^-$ decay, predicted in the Standard Model to be $(7.2\pm0.7)\times 10^{-11}$. Upper limits at 90% CL are obtained at the level of $10^{-9}$ for the branching ratios of two prompt decay chains involving pair-production of hidden-sector mediators: $K^+\to\pi^+aa$, $a\to e^+e^-$ and $K^+\to\pi^+S$, $S\to A^\prime A^\prime$, $A^\prime\to e^+e^-$. The QCD axion is excluded as a possible explanation of the "17 MeV anomaly"

Search for K+K^+ decays into the π+e+e−e+e−\pi^+e^+e^-e^+e^- final state

The first search for ultra-rare $K^+$ decays into the $\pi^+e^+e^-e^+e^-$ final state is reported, using a dataset collected by the NA62 experiment at CERN in 2017-2018. An upper limit of $1.4\times 10^{-8}$ at 90% CL is obtained for the branching ratio of the $K^+\to\pi^+e^+e^-e^+e^-$ decay, predicted in the Standard Model to be $(7.2\pm0.7)\times 10^{-11}$. Upper limits at 90% CL are obtained at the level of $10^{-9}$ for the branching ratios of two prompt decay chains involving pair-production of hidden-sector mediators: $K^+\to\pi^+aa$, $a\to e^+e^-$ and $K^+\to\pi^+S$, $S\to A^\prime A^\prime$, $A^\prime\to e^+e^-$. The QCD axion is excluded as a possible explanation of the '17 MeV anomaly'

Improved calorimetric particle identification in NA62 using machine learning techniques

International audienceMeasurement of the ultra-rare ${K}^{+}\to {\pi}^{+}\nu \overline{\nu}$ decay at the NA62 experiment at CERN requires high-performance particle identification to distinguish muons from pions. Calorimetric identification currently in use, based on a boosted decision tree algorithm, achieves a muon misidentification probability of 1.2 × 10$^{−5}$ for a pion identification efficiency of 75% in the momentum range of 15–40 GeV/c. In this work, calorimetric identification performance is improved by developing an algorithm based on a convolutional neural network classifier augmented by a filter. Muon misidentification probability is reduced by a factor of six with respect to the current value for a fixed pion-identification efficiency of 75%. Alternatively, pion identification efficiency is improved from 72% to 91% for a fixed muon misidentification probability of 10$^{−5}$